DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.

-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. -- -- Company Expects Restructuring to Drive Annual Cost Savings of Approximately $40 Million -- -- Announces

-- VASCEPA ® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT-- -- VASCEPA Becomes First and Only Approved Medication in

-- VASCEPA ® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT-- -- VASCEPA Becomes First and Only Approved Medication in

DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences: